Advertisement

Immunological Treatments in Multiple Sclerosis: Rationale, Results and New Avenues

  • R. E. Gonsette
Part of the Ettore Majorana International Science Series book series (EMISS, volume 16)

Abstract

Cytotoxic drugs have been used in multiple sclerosis (MS) since 1966. At that time however, our understanding of immune mechanisms involved in the development of the disease was very limited.

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Myelin Basic Protein Transfer Factor Intrathecal Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aimard, G., Girard, P. F., and Raveau, J., 1966, Sclerose en plaques et processus d’ autoimmunisation. Traitement par les antimitotiques, lyonMed., 215: 345.Google Scholar
  2. Aimard, G., Confavreux, C., Ventre, J. J., Guillot, M., and Devic, M., 1983, Etude de 213 cas de sclérose en plaques traités par l’azathiorpine de 1967 á 1982, Rev.Neurol., 139: 509.Google Scholar
  3. Aleksandrowicz, J., Skotnicki, A. B., and Zduńczyk, A., 1982, The combined immunomodulatory treatment in patients with multiple sclerosis — A long-term study, Personal Communication.Google Scholar
  4. Baixe, J. H., 1978, Bilan de onze annees d’activité en medicine hyperbare, Med.Aer.Spatiale Med., Subaquatique Hyperbare, 17: 90.Google Scholar
  5. Basten, A., Pollard, J. D., Stewart, G. J., Frith, J. A., McLeod, J. G., Walsh, J. C., Garrick, R., and Van Der Brink, C. M., 1980, Transfer factor in treatment of multiple sclerosis, The Lancet, 11: 931.CrossRefGoogle Scholar
  6. Behan, P. O., Durward, W. F., Melville, I. D., McGeorge, A. P., and Behan, W. M. H., 1976, Transfer factor therapy in multiple sclerosis, The Lancet, 1: 988CrossRefGoogle Scholar
  7. Benczur, M., Petranyi, G. Gy., Palffy, Gy., Varga, M., Talas, M., Kotsy, B., Foldes, I., and Hollan, S. R., 1980, Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor, Clin.Exp.Immunol., 39: 657.Google Scholar
  8. Bolton, C., Borel, J. F., Cuzner, M. L., Davison, A. N., and Turner, A. M., 1982, Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis, J.of the Neurol.Soc., 56: 147.CrossRefGoogle Scholar
  9. Borel, J. F., 1980, Essentials of cyclosporin A. A novel type of antilymphocyte agent, Trends Pharmacol.Sci., 1: 146.CrossRefGoogle Scholar
  10. Bornstein, M. B., Miller, A. I., Teitelbaum, D., Arnon, R., and Sela, M., 1982, Multiple Sclerosis: Trial of a synthetic polypeptide, Ann.Neurol., 11: 317.CrossRefGoogle Scholar
  11. Boschetty, V., and Cernoch, J., 1970, Aplikace kysliku za pretlaku u nekterych Neurologiekych onemochemy, Bratisl.Lek.Listy, 52: 298.Google Scholar
  12. Brinkman, C. J. J., and Homes, O. R., 1982, The effect of cyclophosphamide on T lymphocyte and T lymphocyte subsets in patients with chronic progressive multiple sclerosis, in: “Immunosuppression in Multiple Sclerosis, Proceedings of the Nijmegen Workshop June 10-12, 1982. Clinical trials Journal 1984”. O. Hommes, J. Mertin, W. W. Tourtellotte, eds., (to be published).Google Scholar
  13. Camenga, D. L., 1977, Safety and efficacy of Levamisole in multiple sclerosis, in: “Excerpta Medica Proceedings of the 11th World Congress of Neurology, Amsterdam”.Google Scholar
  14. Campbell, B., Vogel, P. J., Fisher, E., and Lorenz, R., 1973, Myelin basic protein administration in multiple sclerosis, Arch.of Neurol., 29: 10.CrossRefGoogle Scholar
  15. Capparelli, R., Inzitari, D., Sita, D., Guarnieri, B. M., Fratiglioni, L., Amaducci, L., Avanzi, G., Franco, C., and Lombardo, R., 1984, Plasmapheresis in multiple sclerosis: cerebrospinal fluid changes after treatment, in: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds, MTP Press Limited, Lancaster.Google Scholar
  16. Cendrowski, W., and Czlonkowska, A., 1978, Levamisole in multiple sclerosis, with special reference to immunological parameters, Acta.Neurol.Scand., 57: 354.CrossRefGoogle Scholar
  17. Cook, A. W., Carter, W. B., and Nidzgorski, F., 1982, Interferon responses of leukocytes in MS, Neurol., 32:104.Google Scholar
  18. Collins, R. C., Espinoza, L. R., Plank, C. R., Ebers, G. C., Rosenberg, R. A., and Zabriskie, J. B., 1978, A double-blind trial of transfer factor vs placebo in multiple sclerosis patients, Clin.Exp.Immunol., 33: 1.Google Scholar
  19. Dachsel, R., Wieczorek, V., and Voigt, W., 1982, Klinische Langschnittuntersuchungen unter immunsuppressiver therapie bei multipler sklerose, Dt.Gesundh.-Wesen, 37: 2087.Google Scholar
  20. Dau, P. C., Johnson, K. P., and Spitler, L. E., 1976, The effect of levamisole on cellular immunity in multiple sclerosis, Clin. Exp.Immunol., 26: 302.Google Scholar
  21. Dau, P. C., Petajan, J. H., Johnson, K. P., Panitch, H. S., and Bornstein, M. B., 1980, Plasmapheresis in multiple sclerosis: preliminary findings, Neurol., 30: 1023.CrossRefGoogle Scholar
  22. De Saxce, H., Marteau, R., and Lhermitte, F., 1984, Treatment of progressive multiple sclerosis by the combined application of antilymphocyte serum, azathioprine and prednisone, in: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  23. Dominguez, R., Chamoles, N., and Somoza, M., 1978, Intrathecal methotrexate in multiple sclerosis, in: “Humoral Immunity in Neurological Diseases,” D. Karcher, A. Lowenthal, eds, Plenum Press, N. Y., London.Google Scholar
  24. Dworkin, R. H., Bates, D., Millar, J. H. D., Paty, D. W., and Shaw, D. A., 1984, Dietary supplementation with polyunsaturated fatty acids in acute remitting multiple sclerosis, in: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  25. Ferguson, T. B., Clifford, D. B., Montgomery, E. B., Bruns, K. A., McGregor, P. J., and Trotter, 1983, Thymectomy in Multiple Sclerosis. Two preliminary trials, J.Thorac.Cardiovasc.Surg., 85: 88.Google Scholar
  26. Fischer, B. H., Marks, M., and Reich, T., 1983, Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebocontrolled, double-blind study, The New England J. of Med., 308: 181.Google Scholar
  27. Fog, T., Raun, N. E., Pedersen, L., Kam-Hansen, S., Mellerup, E., Platz, P., Ryder, L. P., Jakobsen, B. K., and Grob, P., 1978, Long-term transfer-factor treatment for multiple sclerosis, The Lancet, 1: 851.CrossRefGoogle Scholar
  28. Fog, T., 1980, Interferon treatment of multiple sclerosis patients. A pilot study, in: “Search for the cause of multiple sclerosis and other chronic diseases of the central nervous system,” A. Boese, eds., Verlag Chemie, Weinheim.Google Scholar
  29. Formai, C., Sereni, G., and Zannini, D., 1980, Lfossigenoterapia iperbarica nel trattamento della sclerosi multipla, in: “4th Congresso Nationale di Medicina subacquea ed Iperbarica,” Napoli.Google Scholar
  30. Giordano, G. F., Masland, W., Ketchel, S. J., Holland, K, Tilmann, K, Wallace, B. A., and Jones, R. M., 1982, An investigation of lymphocytapheresis in multiple sclerosis, Plasma Ther.Transfus. Technol., 3: 417.Google Scholar
  31. Gonsette, R. E., Demonty, L., and Delmotte, P., 1977, Intensive immunosuppression with cyclophosphamide in Multiple Sclerosis, Follow-up of 110 patients for 206 years, J.Neurol., 214: 173.CrossRefGoogle Scholar
  32. Gonsette, R. E., Delmotte, P., and Demonty, L., 1977, Failure of basic protein therapy for Multiple Sclerosis, J.Neurol., 216: 27.CrossRefGoogle Scholar
  33. Gonsette, R. E., Demonty, L., Delmotte, P., Decree, J., de Cock, W., Verhaeghen, H., and Symoens, J., 1982, Modulation of immunity in multiple sclerosis: a double-blind levamisole-placebo controlled study in 85 patients, J.Neurol., 228: 65.Google Scholar
  34. Gonsette, R. E., Demonty, L., De Smet, Y., and Delmotte, P., 1984, Immunosuppression with cyclophosphamide in multiple sclerosis, in: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  35. Guarnieri, B. M., Amaducci, L., Cambi, F., Capparelli, R., Arfaioli, C., Avanzi, G., and Franco, C., 1984, Changes of polymorphonuclear neutral proteinase activity in multiple sclerosis patients before and after plasma exchanges, in: “Immunological and clinical aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  36. Guenther, W., Neu, I. S., Koenig, N., and Rothfelder, U., 1984, Experiences with immunoglobulin-G infusions in the treatment of acute multiple sclerosis, In: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  37. Hauser, S. L., Dawson, D. M., Lehrich, J. R., Beal, M. F., Kevy, S. V., Propper, R. D., Mills, J. A., and Weiner, H. L., 1983, Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH, The New Engl.J.of Med., 308: 173.Google Scholar
  38. Hausfer, S. L., Dawson, D. M., and Weiner, H. L., 1983, Immunosuppression for Multiple Sclerosis, letter, New Engl.J.of Med., 309: 241.CrossRefGoogle Scholar
  39. Hommes, O. R., Lamers, K. J. B., and Reekers, P., 1982, Long-term follow-up after intensive immunosuppression of 47 patients with chronic progressive multiple sclerosis, in: “Immunosuppression in Multiple Sclerosis, Proceedings of the Nijmegen Workshop June 10-12, 1982. Clinical Trials Journal 1984,” O. Hommes, J. Mertin, W. W. Tourtellotte, eds, (to be published).Google Scholar
  40. Isomaki, H. A., Mutru, O., and Koota, K., 1975, Death rate and cause of death in patients with rhumatoid arthritis, Scand.J.Rhum., 4: 205.Google Scholar
  41. Jacobs, L., O’Malley, J., Freeman, A., Murawski, J., and Ekes, R., 1982, Intrathecal interferon in multiple sclerosis, Arch. Neurol., 39: 609.Google Scholar
  42. Johnson, K., 1983, Viruses as initiator of central nervous system autoimmune disorders, in: “Symposium on immune regulation and its application to Multiple Sclerosis, Vancouver, Canada”.Google Scholar
  43. Kastrukoff, L . F., McLean, D. R., and McPherson, T. A., 1978, multiple sclerosis treated with antihymocyte globulin — A five year follow-up, J.Cane.Sc.Neurol., 5:175.Google Scholar
  44. Kaudewitz, P., Zander, H., Abb, J., Ziegler-Heitbrock, H. W., and Riethmuller G., 1983, Genetic influence on natural cytotoxicity and interferon production in multiple sclerosis studies in monozygotic discordant twins, Hum.Immunol., 7: 51.CrossRefGoogle Scholar
  45. Kennes, B., Leroy, C-P., Dumont, J-P., Brohee, D., Jacquy, J., Noel, G., and Neve, P., 1984, Lympho-plasmapheresis in multiple sclerosis: effect on clinical and immunological parameters, in: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  46. Kindwall, E. P., 1983, National multiple sclerosis registry, HBO Review, 4: 38.Google Scholar
  47. Kolar, O. J., 1983, Clinical application of examination of CSF subpopulation of T cells, in: “International Workshop on multiple sclerosis, Erice.”Google Scholar
  48. Lamoureux, G., Cosgrove, J., Duquette, P., Lapierre, Y., Jolicoeur, R., and Vanderland, F., 1981, A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients, Clin.Exp.Immunol., 43: 557.Google Scholar
  49. Lauer, K., Firnhaber, W., and John, D., 1984, Longterm treatment with azathioprine in multiple sclerosis patients, in: “Immunological and clinical aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  50. Levine, S., and Swoinski, R., 1977, Suppression of the hyperacute form of experimental allergic encephalomyelitis by drugs, Arch.int.Pharmacodyn., 230: 309.Google Scholar
  51. McFarland, H. F., and Rose, J. W., 1982, Lymphocytapheresis in the treatment of multiple sclerosis, Plasma Ther Transfus Techn., 3: 411.Google Scholar
  52. Massaro, A. R., and Burrai, I., 1981, Levamisole treatment in multiple sclerosis, in: “Excerpta Medica. Proceedings of the 12th World Congress of Neurology, Kyoto”.Google Scholar
  53. Mertin, J., Kremer, M., Knight, S. C., Batchelor, J. R., Halliday, A. M., Rudge, P., healey, M. J. R., Compston, A., Thompson, E. J., and Denman, M., 1982, Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report, The Lancet 11: 351.CrossRefGoogle Scholar
  54. Myers, L. W., Ellison, G. W., Levy, J., Holevoet, M., and Tourtellotte, W. W., 1977, Experience with Levamisole in multiple sclerosis, in: “Excerpta Medica.Proceedings of the 11th World Congress of Neurology, Amsterdam”.Google Scholar
  55. Neighbour, P. A., and Bloom, B. R., 1979, Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis, Proc.Natl.Acad.Sci.USA, 76: 476.ADSCrossRefGoogle Scholar
  56. Neighbour, P. A., Miller, A. E., and Bloom, B. R., 1981, Interferon responses of leucocytes in multiple sclerosis, Neurol., 31: 561.CrossRefGoogle Scholar
  57. Neubauer, R. A., 1980, Exposure of multiple sclerosis patients to hyperbaric oxygen at 1,5-2 ATA: a preliminary report, J. Fla. Med.Assoc., 67: 498.Google Scholar
  58. Oger, J. J-F., Antel, J. P., Kuo, H. H., and Arnason, B. G. W., 1982, Influence of azathioprine ( Imuran) on in vitro immune function in multiple sclerosis, Ann.Neurol., 11: 177.CrossRefGoogle Scholar
  59. Pallotta, R., Anceschi, S., and Costagliola, N., 1980, Prospettive di terapia iperbarica nella Sclerosi a Placche, Ann.Med.Navale, 85: 57.Google Scholar
  60. Patzold, U., Haller, P., Haas, J., Pocklington, P., and Dreicher, H., 1979, Therapie der Multiplen Sklerose mit Levamisole und Azathioprin, Nervenarzt, 49: 285.Google Scholar
  61. Patzold, U., Hecker, H., and Pocklington, P., 1982, Azathioprine in treatment of multiple sclerosis. Final results of a 4% year controlled study of its effectiveness covering 115 patients, J.Neurol.Sci., 54: 377.CrossRefGoogle Scholar
  62. Patzold, U., and Haas, J., 1982, Adverse effects of longterm treatment with azathioprine, in: “Immunosuppression in Multiple Sclerosis, Proceedings of the Nijmegen Workshop, June 10-12, 1982. Clinical trials Journal 1984”, O. Hommes, J. Mertin, W. W. Tourtellotte, eds., (to be published).Google Scholar
  63. Raine, C. S., and Traugott, U., 1983, Chronic relapsing experimental autoimmune encephalomyelitis. Ultrastructure of the central nervous system of animals treated with combinations of myelin components, Labor. Invest., 48: 275.Google Scholar
  64. Romine, J. S., and Salk, J., 1983, A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis, in: “Multiple Sclerosis,” J. F. Hallpike, C. W. Adams, W. W. Tourtellotte, eds., Chapman and Hall, London.Google Scholar
  65. Rosen, J. A., 1979, Prolonged azathioprine treatment of non-remitting multiple sclerosis, J.Neurol.Neurosurg. & Psych., 42: 338.Google Scholar
  66. Rosen, A. D., and Hamburger, M. I., 1981, Plasmapheresis in multiple sclerosis: effect on the visual evoked potential, Plasma Ther. Transfus.Techn., 2: 239.Google Scholar
  67. Ruutiainen, J., Panelius, M., and Cantell, K., 1983, Toxic effects of interferon administered intrathecally, British Med.J., 286: 940.CrossRefGoogle Scholar
  68. Sabouraud, O., Madigand, M., and Merienne, M., 1982, Continuous immuno-suppressive therapy for multiple sclerosis: appraisal of 67 cases started before 1972, in: “Immunosuppression in Multiple Sclerosis, Proceedings of the Nijmegen Workshop. June 10-12, 1982. Clinical trials Journal 1984” O. Hommes, J. Mertin, W. W. Tourtellotte, eds., (to be published).Google Scholar
  69. Salonen, R., Ilonen, J., Reunanen, M., and Salmi, A., 1982, Defective production of interferon-alpha associated with HLADW2 antigen in stable multiple sclerosis, J.Neurol.Sc., 55: 197.CrossRefGoogle Scholar
  70. Santoli, D., Hall, W., Kastrukoff, L., Lisak, R. P., Perussia, B., Trinchieri, G., and Koprowski, H., 1981, Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis, J.of Immunol., 126: 1274.Google Scholar
  71. Schuller, E., and Govaerts, A., 1983, First results of immunotherapy with immunoglobulin G in multiple sclerosis patients, Eur. Neurol., 22: 205.Google Scholar
  72. Seidenfeld, A. M., Smythe, H. A., Ogryzlo, M. A., Urowitz, M. B., and Dotten, D. A., 1976, Acute leukemia in rheumatoid arthritis treated with cytotoxic agents, J.Rheum., 3: 295.Google Scholar
  73. Seil, F. J., Westall, F. C., Romine, J. S., and Salk, J., 1983, Serum demyelinating factors in multiple sclerosis, Ann.Neurol., 13: 664.CrossRefGoogle Scholar
  74. Shih, W. W. H., Baumhefner, R. W., Tourtellotte, W. W., Haskell, C. M., Korn, E. L., and Fahey, J. L., 1983, Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis, Clin.Exp.Immunol., 53: 122.Google Scholar
  75. Stefoski, D., Schauf, C. L., McLeod, B. C., Haywood, C. P., and Davis, F. A., 1982, Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis, Neurol., 32: 904.CrossRefGoogle Scholar
  76. Tourtellotte, W. W., Potvin, A. R., Mendez, M., Baumhefner, R. W., Potvin, J. H., Ma, B.I., and Syndulko, K., 1980, Failure of intravenous and intrathecal cytarabine to modify central nervous system IgG synthesis in multiple sclerosis, Ann.Neurol., 8: 402.CrossRefGoogle Scholar
  77. Tovell, D. R., McRobbie, I. A., Warren, K. G., and Tyrrell, D. L. J., 1983, Interferon production by lymphocytes from multiple sclerosis and non-MS patients, Neurol., 33: 640.CrossRefGoogle Scholar
  78. Trotter, J. L., Rodey, G. E., and Gebel, H. M., 1982, Azathioprine decreases suppressor T cells in patients with multiple sclerosis, The New Engl.J. of Med., 306: 365.Google Scholar
  79. Turk, J. L., and Parker, D., 1979, The effect of cyclophosphamide on the immune response, J. of Immunopharmacol., 1: 127.CrossRefGoogle Scholar
  80. Valbonesi, M., Garelli, S., Mosconi, L., Zerbi, D., and Forlani, G., 1981, Plasma exchange in the management of patients with multiple sclerosis: preliminary observations, Vox Sang., 41: 68.CrossRefGoogle Scholar
  81. Van Haver, H., Lissoir, F., Theys, P., Droissart, Chr., Van Hees, J., Ketelaer, P., Carton, H., Gautama, K., Vandeputte, I., and Vermylen, C., 1984, Transfer factor treatment in MS: a 3 year prospective double-blind study (1982-1985), in: “Immunological and Clinical Aspects of Multiple Sclerosis,” R. E. Gonsette, P. Delmotte, eds., MTP Press Limited, Lancaster.Google Scholar
  82. Ververken, D., Carton, H., and Billiau, A., 1979, Intrathecal administration of interferon in MS patients, in: “Humoral Immunity in Neurological Diseases,” D. Karcher, A. Lowenthal, eds., Plenum Press, N. Y. and London.Google Scholar
  83. Vervliet, G., Claeys, H., Van Haver, H., Carton, H., Vermylen, C., Meulepas, E., and Billiau, A., 1983, Interferon production and natural killer ( NK) activity in leukocyte cultures from multiple sclerosis patients, J.Neurol.Sci., 60: 137.CrossRefGoogle Scholar
  84. Warren, J., Sacksteder, M. R., and Thuning, C. A., 1978, Oxygen immunosuppression: modification of experimental allergic encephalomyelitis in rodents, J. of Immunol., 121:315.Google Scholar
  85. Weiner, H. L., Dawson, D. M., 1980, Plasmapheresis in multiple sclerosis: preliminary study, Neurol., 30: 1029.CrossRefGoogle Scholar
  86. Zander, H., Abb, J., Kaudewitz, P., and Riethmuller, G., 1982, Natural killing activity and interferon production in multiple sclerosis, The Lancet, 1: 280.CrossRefGoogle Scholar
  87. Zeeberg, I., Heltberg, A., Kristensen, J. K., Raun, N. E., and Fog, T., 1982, A longterm double-blind, controlled trial - of azathioprine versus placebo, - in treatment of progressive multiple sclerosis, in: “Immunosuppression in multiple sclerosis, Proceedings of the Nigmegen Workshop June 10-12, 1982. Clinical Trials Journal,” O. Hommes, J. Mertin, W. W. Tourtellotte, eds., (to be published).Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • R. E. Gonsette
    • 1
  1. 1.Belgian National Centre for Multiple SclerosisMelsbroekBelgium

Personalised recommendations